Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491329 | 1.00 | SLC6A4 (0.63) | SLC6A4DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL30275187 | 0.81 | HTR2A (0.64) | SLC6A4DRD2HTR2AHTR1AADRA1D | |
| SCHEMBL2904310 | 0.81 | HTR2A (0.64) | SLC6A4DRD2HTR2AHTR1AADRA1D | |
| SCHEMBL8631277 | 0.80 | HTR2C (0.65) | SLC6A4HTR2AADRA1D | |
| Hydrochloric Acid SCHEMBL6248133 | 0.80 | HTR2C (0.63) | SLC6A4DRD2HTR2AHTR1AADRA1D | |
| SCHEMBL31295107 | 0.79 | HTR2A (0.69) | SLC6A4DRD2HTR2AHTR1AADRA1D | |
| SCHEMBL5097759 | 0.79 | HTR2A (0.69) | SLC6A4DRD2HTR2AHTR1AADRA1D | |
| SCHEMBL5097763 | 0.79 | HTR2A (0.69) | SLC6A4DRD2HTR2AHTR1AADRA1D | |
| SCHEMBL6088301 | 0.77 | SLC6A4 (1.00) | SLC6A4HTR2AHTR1ADRD1SLC6A2 | |
| Lithium Ion SCHEMBL31530810 | 0.77 | HTR2A (0.66) | SLC6A4DRD2HTR2AHTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844338-B2 | Piperidyindoles as serotonin receptor ligands | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030225068-A1 | Piperidyindoles as serotonin receptor ligands | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1286992-A1 | PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087881-A1 | PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225068-A1 | Piperidyindoles as serotonin receptor ligands | CNR1, HTR1D, HTR1A | SLC6A4 215/4885DRD2 16/4885HTR2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.